drugset / Trial / NCT06805825
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Non-randomizedSequentialOpen-labelTreatment
Summary
This open-label clinical trial will evaluate the safety and tolerability of NN3201 in subjects with advanced and/or metastatic solid tumors known to express c-Kit.
Timeline
- Start
- 2025-02-03
- Primary completion
- 2027-08-30
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NN3201 | Monoclonal antibody | — | Intravenous |